DRUG Stock Forecast: Bright Minds Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$20

The median 12-month analyst price target for Bright Minds Biosciences, Inc. is $110. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 17 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$201.2M
Ticker Nerd rank
17/ 100
Median analyst target
$110
Analysts covering
9
Revenue$0.0
Operating income−$11.4M
Net income−$2.4M
Free cash flow−$8.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Bright Minds Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
17/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
76
Revisions
37
Issuance
29
Momentum
29
Value
24
Accruals
19
Growth
18
Volatility
14

Quality (76): The business earns solid, repeatable profits on what it owns.

Volatility (14): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DRUG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DRUG, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says9 analysts
9
Buy
0
Hold
0
Sell
$36
Low
$110
Median
$146
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Nov 2026BairdMaintainsOutperform$126 → $107
2 Nov 2026BTIGMaintainsBuy$147 → $37
15 Oct 2026Wolfe ResearchInitiatesOutperform—
19 Aug 2026HC Wainwright & Co.ReiteratesBuy$145
17 Aug 2026BTIGReiteratesBuy$147
1 June 2026HC Wainwright & Co.ReiteratesBuy$145
20 May 2026Piper SandlerMaintainsOverweight—
13 Apr 2026JefferiesInitiatesBuy—
30 Mar 2026BTIGReiteratesBuy—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
17 Feb 2026BTIGMaintainsBuy—
7 Jan 2026BTIGMaintainsBuy—
6 Jan 2026BTIGMaintainsBuy—
2 Jan 2026Chardan CapitalMaintainsBuy—
30 Dec 2025HC Wainwright & Co.ReiteratesBuy—
15 Sept 2025HC Wainwright & Co.ReiteratesBuy—
8 Sept 2025BTIGInitiatesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
2 July 2025Cantor FitzgeraldAssumesOverweight—
21 May 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DRUG.

Market Radar

This page is one stock. Monday covers all of them.

DRUG appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

DRUG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.9×

Cheaper than 74% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−13.6%

Higher than 35% of US stocks

Return on assets
−13.5%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bright Minds Biosciences, Inc. has a market value of $201.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$24.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$24.7M.

  • Shares outstanding: 9.8M.

  • Bright Minds Biosciences, Inc. employs 26 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

DRUG and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DRUGBright Minds Biosciences, Inc.$201.2M17
ACIUAC Immune SA$198.5M66
NGENNervGen Pharma Corp.$198.4M33
YARWYarrow Bioscience, Inc.$196.5M37
ACOGAlpha Cognition, Inc.$196.0M53
CABACabaletta Bio, Inc.$201.9M28
FTHFaeth Therapeutics, Inc.$203.1M26

Take a look at DRUG’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Bright Minds Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about DRUG

What is the DRUG stock price forecast for 2026-2027?

The median 12-month analyst price target for Bright Minds Biosciences, Inc. is $110, with estimates ranging from $36 to $146. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DRUG stock a buy right now?

Of the 9 analysts covering Bright Minds Biosciences, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bright Minds Biosciences, Inc. 17 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DRUG?

As at 21 Nov 2026, Bright Minds Biosciences, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (76 of 100).

Will DRUG stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts is $110, and Ticker Nerd's factor model ranks Bright Minds Biosciences, Inc. 17 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DRUG stock forecast for 2030?

No analyst covering Bright Minds Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRUG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $146 over the next 12 months.

What does Bright Minds Biosciences, Inc. do?

Bright Minds Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapeutics for neurological and psychiatric disorders. Bright Minds Biosciences Inc. works on next-generation compounds targeting serotonin receptor pathways, with programs aimed at conditions such as epilepsy, depression, pain, and other central nervous system disorders.

Company

About Bright Minds Biosciences, Inc.

Bright Minds Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapeutics for neurological and psychiatric disorders. Bright Minds Biosciences Inc. works on next-generation compounds targeting serotonin receptor pathways, with programs aimed at conditions such as epilepsy, depression, pain, and other central nervous system disorders. The company’s research emphasizes selective small-molecule drug candidates designed to address severe and life-altering diseases with high unmet medical need. Its current business is centered on drug discovery and development, supported by a pipeline of preclinical and clinical programs in neurology and psychiatry. Bright Minds Biosciences Inc. operates as a research-driven biotech platform focused on advancing novel therapeutics from early development toward potential clinical use.

CEO Mr. Ian McDonald · 26 employees · United States · https://brightmindsbio.com